Aristeia Capital’s Colombier Acquisition Corp. II Warrants, each whole warrant exercisable for one Class A Ordinary Share at an exercise price of $11.50 per share CLBR.WS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-170,871
Closed -$640K 549
2025
Q2
$640K Buy
+170,871
New +$383K 0.02% 192

Aristeia Capital's CLBR.WS Position: Q3 2025 in Review

Aristeia Capital sold out of Colombier Acquisition Corp. II Warrants, each whole warrant exercisable for one Class A Ordinary Share at an exercise price of $11.50 per share (CLBR.WS) in Q3 2025, closing a stake of 170,871 shares — an estimated $640K sold.

Aristeia Capital first reported a position in CLBR.WS in Q2 2025 and held it in 1 quarter. The position peaked at $640K in Q2 2025. 0 funds tracked by Wall St. Rank hold CLBR.WS as of Q3 2025.

  • Aristeia Capital reported no remaining Colombier Acquisition Corp. II Warrants, each whole warrant exercisable for one Class A Ordinary Share at an exercise price of $11.50 per share position as of Q3 2025 after selling out during the quarter.
  • Aristeia Capital sold 170,871 Colombier Acquisition Corp. II Warrants, each whole warrant exercisable for one Class A Ordinary Share at an exercise price of $11.50 per share shares in Q3 2025, an estimated $640K.
  • Aristeia Capital first reported a position in Colombier Acquisition Corp. II Warrants, each whole warrant exercisable for one Class A Ordinary Share at an exercise price of $11.50 per share in Q2 2025 and held it in 1 quarter.
  • Aristeia Capital's Colombier Acquisition Corp. II Warrants, each whole warrant exercisable for one Class A Ordinary Share at an exercise price of $11.50 per share position peaked at $640K in Q2 2025.
  • 0 funds tracked by Wall St. Rank held Colombier Acquisition Corp. II Warrants, each whole warrant exercisable for one Class A Ordinary Share at an exercise price of $11.50 per share as of Q3 2025.

Based on Aristeia Capital's 13F filing for Q3 2025, filed 14 Nov 2025.